Washington.- U.S. health authorities will test the intradermal administration of one-tenth of the monkeypox vaccine, something they hope will help double the amount of vaccine available in other countries.
Currently, some countries (including the USA) allow the intradermal administration of a fifth of the vaccine – a form of vaccination that involves sticking the needle between the layers of the skin, rather than through it -, which has allowed to increase the number of doses available.
“We have enough doses in the United States to deal with people at risk, but this is a global problem,” the country’s chief epidemiologist Anthony Fauci explained Thursday during a press conference on the White House response to the coronavirus. outbreak.
According to Fauci, the study, which will soon be conducted in the country, will serve to determine whether the intradermal inoculation of a tenth of the vaccine produces a similar immune response, and is just as safe as the subcutaneous administration – through the skin -, which is the most widespread. .
During the press conference, several experts from the government’s monkeypox response team celebrated the decline in new infections the country has been experiencing in recent days, which they attributed to the success of the vaccination program and efforts to educate the population. .
However, health authorities have warned that there is a large inequality between the people most affected by the virus and those who are vaccinated.
According to data from the Centers for Disease Control (CDC), blacks account for nearly 40% of new cases registered, but only 12% of those vaccinated.
Whites, on the other hand, who account for 26% of new infections, also account for 47% of those who have received at least one dose of the vaccine.
Latins account for 25% of new infections and 21% of vaccinated ones.
To try to expand vaccine coverage, U.S. health authorities will extend their pilot vaccination program at festivals and events targeting the LGBT community to include smaller acts. EFE
–
